Research Centers
Biocon Biologics’ world-class Research & Development (R&D) centers in Bengaluru and Chennai are integral to our mission of developing high-quality, affordable biosimilars that expand global access to life-saving therapies. The centers collaborate seamlessly, pushing the boundaries of biosimilar development, with a focus on accelerating the development of our biosimilars from lab to market, ensuring that affordable therapies reach patients swiftly.
Our fully integrated R&D facilities are part of a rich scientific ecosystem that fosters innovation and excellence, and are dedicated to developing high-quality biosimilars, including recombinant insulins, monoclonal antibodies, and other protein therapeutics, for highly regulated markets such as the U.S., Europe, Canada, Australia, and Japan, as well as emerging markets. This commitment ensures that we remain at the forefront of biopharmaceutical innovation, delivering impactful solutions to patients, worldwide.
Bengaluru
Chennai
Our 60,000 sq. ft. R&D center at TICEL Bio Park, Chennai, is focused on accelerating development of innovative biosimilar solutions from bench to pilot scale. Acquired from Pfizer Healthcare India Ltd. in 2019, this facility has contributed to expanding Biocon Biologics’ R&D capabilities, helping us move closer to our commitment of meeting the healthcare needs of millions of patients worldwide. Its advanced infrastructure enables rapid development and optimization, playing a key role in our R&D value chain.
